These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 33189019)

  • 1. A real-world cohort analysis of alemtuzumab outcomes in relapsing multiple sclerosis.
    Herman JA; Khalighinejad F; York K; Radu I; Berrios Morales I; Ionete C; Hemond CC
    Mult Scler Relat Disord; 2021 Jan; 47():102619. PubMed ID: 33189019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis.
    Bose G; Rush C; Atkins HL; Freedman MS
    Mult Scler Relat Disord; 2021 Jul; 52():102945. PubMed ID: 33901969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study.
    Prosperini L; Annovazzi P; Boffa L; Buscarinu MC; Gallo A; Matta M; Moiola L; Musu L; Perini P; Avolio C; Barcella V; Bianco A; Farina D; Ferraro E; Pontecorvo S; Granella F; Grimaldi LME; Laroni A; Lus G; Patti F; Pucci E; Pasca M; Sarchielli P;
    J Neurol; 2018 Dec; 265(12):2851-2860. PubMed ID: 30259178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Retrospective Analysis of Alemtuzumab Outcomes in Relapsing-Remitting Multiple Sclerosis: The LEMCAM Study.
    Costa-Frossard França L; Meca Lallana V; Labiano-Fontcuberta A; Blasco R; Monreal E; Martínez Ginés ML; Aguirre C; Sabin Muñoz J; Sainz de la Maza S; Cuello JP; Díaz-Pérez C; Chico García JL; Lozano Ros A; Rodríguez Jorge F; Martínez Martínez S; García Domínguez JM
    CNS Drugs; 2024 Mar; 38(3):231-238. PubMed ID: 38418770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A real-life study of alemtuzumab in persons with multiple sclerosis: Kuwait's experience.
    Alroughani R; AlMojel M; Al-Hashel J; Ahmed SF
    Mult Scler Relat Disord; 2023 Jun; 74():104712. PubMed ID: 37054581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of alemtuzumab in the treatment of active relapsing-remitting multiple sclerosis: a multicenter, observational study.
    Brecl Jakob G; Barun B; Gomezelj S; Gabelić T; Šega Jazbec S; Adamec I; Horvat Ledinek A; Rot U; Krbot Skorić M; Habek M
    Neurol Sci; 2021 Nov; 42(11):4591-4597. PubMed ID: 33660157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alemtuzumab treatment in real clinical practice: Experience in a multicenter cohort.
    López-Real AM; Gonzalez I; Solar DM; Oterino A; Costa E; Pato A; Llaneza MA; García-Estévez DA; Rodriguez-Regal A; Rodriguez M; Peña J
    Mult Scler Relat Disord; 2023 Jul; 75():104762. PubMed ID: 37229800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.
    Coles AJ; Cohen JA; Fox EJ; Giovannoni G; Hartung HP; Havrdova E; Schippling S; Selmaj KW; Traboulsee A; Compston DAS; Margolin DH; Thangavelu K; Chirieac MC; Jody D; Xenopoulos P; Hogan RJ; Panzara MA; Arnold DL;
    Neurology; 2017 Sep; 89(11):1117-1126. PubMed ID: 28835403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal assessment of neurocognitive function in people with relapsing multiple sclerosis initiating alemtuzumab in routine clinical practice: LEM-COG study results.
    Wilken J; Traboulsee A; Nelson F; Ionete C; Kolind S; Fratto T; Kane R; Gandhi R; Rawlings AM; Roesch N; Ozog MA; DeLuca J;
    Mult Scler Relat Disord; 2023 May; 73():104677. PubMed ID: 37028124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
    Hersh CM; Cohen JA
    Immunotherapy; 2014; 6(3):249-59. PubMed ID: 24762071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe.
    Alcalá C; Gascón F; Pérez-Miralles F; Domínguez JA; Gil-Perotín S; Casanova B
    J Neurol; 2019 Mar; 266(3):726-734. PubMed ID: 30661133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alemtuzumab treatment of multiple sclerosis in real-world clinical practice: A report from a single Italian center.
    di Ioia M; Di Stefano V; Farina D; Di Tommaso V; Travaglini D; Pietrolongo E; Sensi SL; Onofrj M; De Luca G
    Mult Scler Relat Disord; 2020 Feb; 38():101504. PubMed ID: 31733426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD).
    Vukusic S; Brassat D; de Seze J; Izquierdo G; Lysandropoulos A; Moll W; Vanopdenbosch L; Arque MJ; Kertous M; Rufi P; Oreja-Guevara C
    Mult Scler Relat Disord; 2019 Apr; 29():7-14. PubMed ID: 30654246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis.
    Frau J; Coghe G; Lorefice L; Fenu G; Musu L; Cocco E
    J Neurol; 2019 Jun; 266(6):1405-1411. PubMed ID: 30863891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study.
    Frau J; Saccà F; Signori A; Baroncini D; Fenu G; Annovazzi P; Capobianco M; Signoriello E; Laroni A; La Gioia S; Sartori A; Maniscalco GT; Bonavita S; Clerico M; Russo CV; Gallo A; Lapucci C; Carotenuto A; Sormani MP; Cocco E;
    J Neurol; 2019 Oct; 266(10):2440-2446. PubMed ID: 31209573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute leukocytosis during alemtuzumab treatment in patients with active relapsing-remitting multiple sclerosis.
    Iovino A; Aruta F; Carotenuto A; Manganelli F; Iodice R
    Mult Scler Relat Disord; 2019 Feb; 28():98-100. PubMed ID: 30580038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian study.
    Lapucci C; Frau J; Cocco E; Coghe G; Petracca M; Lanzillo R; Brescia Morra V; Nicoletti CG; Landi D; Marfia G; Vercellino M; Cavalla P; Bianco A; Mirabella M; Torri Clerici V; Tomas E; Ferrò MT; Grossi P; Nozzolillo A; Moiola L; Zaffaroni M; Ronzoni M; Pinardi F; Novi G; Cellerino M; Uccelli A; Inglese M
    Mult Scler; 2024 Aug; 30(9):1151-1162. PubMed ID: 39143825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy.
    Havrdova E; Arnold DL; Cohen JA; Hartung HP; Fox EJ; Giovannoni G; Schippling S; Selmaj KW; Traboulsee A; Compston DAS; Margolin DH; Thangavelu K; Rodriguez CE; Jody D; Hogan RJ; Xenopoulos P; Panzara MA; Coles AJ;
    Neurology; 2017 Sep; 89(11):1107-1116. PubMed ID: 28835401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis.
    Hartung HP; Aktas O; Boyko AN
    Mult Scler; 2015 Jan; 21(1):22-34. PubMed ID: 25344374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary embolism during the third cycle of alemtuzumab in a patient with relapsing multiple sclerosis.
    Habek M; Ruška B; Pavičić T; Alduk AM; Gabelić T; Adamec I
    Mult Scler Relat Disord; 2019 Oct; 35():5-6. PubMed ID: 31276912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.